Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Recruiting 4Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Genitourinary 7

Conditions

Lymphoma, Large B-Cell, Diffuse 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Prostatic Neoplasms 7Lymphoma 5Burkitt Lymphoma 5Neoplasms 4Leukemia, Biphenotypic, Acute 4Ovarian Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3Lymphoma, Follicular 3Hodgkin Disease 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Leukemia 2Endometrial Neoplasms 2Down Syndrome 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Neoplasm Metastasis 1Myasthenia Gravis 1Lymphoma, T-Cell, Peripheral 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Immunoblastic Lymphadenopathy 1Heart Failure 1Enteropathy-Associated T-Cell Lymphoma 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

enzalutamide 94Magnetic Resonance Spectroscopy 85Specimen Handling 66Prednisone 64Androgen Antagonists 59Abiraterone Acetate 58apalutamide 56Radiosurgery 52darolutamide 48Radiotherapy 47Leuprolide 47abiraterone 45Docetaxel 42Pluvicto 32Biopsy 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Radiation 30relugolix 28Surveys and Questionnaires 28gallium 68 PSMA-11 26Standard of Care 26pembrolizumab 25Goserelin 25Triptorelin Pamoate 24Gonadotropin-Releasing Hormone 23bicalutamide 22Brachytherapy 21Carboplatin 20cabazitaxel 19X-Rays 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Prednisolone × 1 year × Clear all
NCT06925737 2026-05-29

MK-2400-001

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,440 enrolled
Genitourinary

Prostatic Neoplasms

NCT06952803 2026-05-19

EvoPAR-PR02

AstraZeneca

Phase 3 Recruiting
700 enrolled
Genitourinary

Prostatic Neoplasms

NCT06764485 2026-05-06

rechARge

Celgene

Phase 3 Recruiting
960 enrolled
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07005154 2026-05-01

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Astellas Pharma Inc

Phase 2 Recruiting
218 enrolled
Genitourinary

Prostatic Neoplasms

NCT02125617 2026-01-14

uPARCRPC

Rigshospitalet, Denmark

Terminated
3 enrolled
Genitourinary

Prostatic Neoplasms

NCT04034095 2025-12-15

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Janssen Pharmaceutical K.K.

Completed
979 enrolled
Genitourinary

Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

Eli Lilly and Company

Phase 3 Active not recruiting
925 enrolled 12 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡